HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

More Criminal Cases Likely In Supplement, Food Safety, DoJ Official Says

This article was originally published in The Tan Sheet

Executive Summary

The Obama administration supports pressing criminal charges in cases of contaminated or adulterated supplements or food products, and the Department of Justice is “working closely” with FDA’s food safety center, says DoJ Consumer Protection Branch official Jeffrey Steger.

You may also be interested in...



FDA Using “All Available Tools” To Remove DMAA From Market

FDA issues a consumer warning about the potentially lethal effects of DMAA, and promises to use “all available tools at its disposal to ensure the dietary supplements containing” the stimulant “are no longer distributed and available for sale.”

FDA Enforces Consent Decree Over J&J/McNeil's OTC Manufacturing

FDA will wield tight oversight of Johnson & Johnson subsidiary McNeil Consumer Healthcare's OTC manufacturing operations under a consent decree filed after the firm's quality-control changes failed to satisfy the agency.

US FDA Touts Benefits From Remote Assessments, Manufacturers Feel Burden – Trade Groups

CHPA members’ feedback on RRAs indicate that “time and resources saved by FDA do not translate to time saved by the manufacturer.” CRN suggests FDA “clearly identify the purpose of the RRA in its initial request and limit requested documents to only those directly related to the purpose of the RRA.”

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

RS124019

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel